For the quarter ending 2025-09-30, DTIL had -$13,594K decrease in cash & cash equivalents over the period. -$15,270K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net (loss) income | -21,772 | -44,085 |
| Depreciation and amortization | 350 | 773 |
| Share-based compensation | 2,386 | 5,759 |
| Loss on disposal of assets | 3 | -34 |
| Non-cash interest expense | 18 | 146 |
| Amortization of right-of-use assets | 324 | 628 |
| Loss (gain) on changes in other fair value adjustments | -3 | -2,415 |
| (gain) loss from equity method investment | -591 | 677 |
| Amortization of discount on note receivable | 231 | 451 |
| Loss (gain) on change in fair value of warrant liability | -1,179 | -51 |
| Prepaid expenses | -1,593 | 1,009 |
| Marketable securities | 0 | -464 |
| Convertible note receivable | 0 | - |
| Accounts receivable | 4 | -229 |
| Contract asset | 0 | -1,469 |
| Other assets and other current assets | 106 | 45 |
| Accounts payable | 220 | 93 |
| Other liabilities and other current liabilities | 528 | -4,441 |
| Deferred revenue | -9 | -43 |
| Lease liabilities | -337 | -633 |
| Net cash used in operating activities | -15,270 | -39,323 |
| Purchases of property, equipment and software | 0 | 66 |
| Purchases of intangible assets | 0 | 265 |
| Proceeds from sale of equipment | 17 | 5 |
| Net cash used in investing activities | 17 | -326 |
| Proceeds from employee stock purchase plan | 78 | 140 |
| Proceeds from issuance of common stock and warrants through underwritten offering, net of issuance cost | 0 | 0 |
| Proceeds from issuance of common stock through atm facility, net of issuance cost | 1,581 | 14,816 |
| Proceeds from issuance of common stock to collaboration partners and licensees | 0 | 1,031 |
| Repayment of revolving credit facility | 0 | - |
| Borrowings from term loan debt facility, net of issuance costs paid to lender | 0 | - |
| Net cash provided by financing activities | 1,659 | 15,987 |
| Net (decrease) increase in cash and cash equivalents | -13,594 | -23,662 |
| Cash and cash equivalents at beginning of period | 108,468 | - |
| Cash and cash equivalents at end of period | 71,212 | - |
PRECISION BIOSCIENCES INC (DTIL)
PRECISION BIOSCIENCES INC (DTIL)